Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer

Exclusion Criteria

• •1. New York Heart Association (NYHA) class ≥Ⅱ heart failure.
• •2. Known or suspected hypersusceptibility to any agents used in the treatment protocol.
• •3. Need to Concurrent treatment with any other anti-cancer therapy considered by the investigator.
• •4. participating in other clinical trials within 4 weeks before this study.
• •5. Serious heart disease, including but not limited to:
• •1\) Significant ventricular arrhythmia or high degree atrioventricular block (Mobitz II or third degree atrioventricular block); 2) unstable angina; 3) clinically significant heart valve disease; 4) Electrocardiogram shows transmural myocardial infarction; 5) Uncontrolled hypertension. 6. Uncontrolled diabetes. 7. Severe or uncontrolled infection. 8. Hepatitis b surface antigen positive, or hepatitis c virus antibody positive, or human immunodeficiency virus (HIV) antibody positive.
• •9\. Active malignancy, other than adequately treated carcinoma in situ of the cervix or basal cell carcinoma of the skin，within the past 5 years.
• •9）Women who are pregnant , breastfeeding ,or refuse to use adequate contraception prior to study entry and for the duration of study participation.
• •10）Other conditions considered to be inappropriate to be enrolled by the investigator.